ArticleFrontiers in aging neuroscience2026
H-ferritin nanoparticle-mediated antibody delivery across the blood-brain barrier.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Therapeutic monoclonal antibodies (mAbs) show great promise for treating neurological disorders thanks to their high selectivity and potency. However, their clinical potential is significantly limited by poor penetration across the blood-brain barrier (BBB). It has been shown that antibodies targeting transferrin receptor 1 (TfR1) can reach the brain after peripheral administration. In addition, human H-ferritin (HFn) naturally undergoes TfR1-mediated transcytosis, making it a compelling alternative candidate platform for brain-directed drug delivery. This study evaluates the feasibility of using HFn as a generic shuttle to transport therapeutic antibodies into the brain. Methods: An anti-BACE1 monoclonal antibody (1A11) was chemically conjugated to HFn, and the resulting nanoparticles (1A11-HFn NPs) were assessed Results: 1A11-HFn NPs were successfully generated with confirmed dual binding to hBACE1 and hTfR1. TEM imaging verified the structural integrity of the nanoparticles. Conclusion: These findings demonstrate that HFn can serve as an effective shuttle to deliver mAbs across the BBB at pharmacologically relevant concentrations. This work provides foundational evidence supporting HFn-based nanoparticles as a promising platform for brain-targeted delivery of biological therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.